secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001477932-24-006916
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx appoints Timothy Still as Chairman, effective November 6, 2024
-------------------------------------------------------------------------

- Timothy Still appointed non-executive Chairman and director of VolitionRx; board expanded to 8 members.
- Still has 35+ years in diagnostics, most recently President/CEO of Sense Biodetection (merged with Sherlock).
- Compensation includes $30K/quarter retainer, 400K time-vested RSUs, and 1M performance-based RSUs tied to $2.50/$5.00 stock price targets.
- Annual RSU grant of 300K shares contingent on corporate goals, subject to share availability under incentive plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793224006916/0001477932-24-006916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793224006916/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-006916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer